Background
SS, Synovial sarcoma
SOFT TISSUE SARCOMAS, SYNOVIAL SARCOMA, STS
Synovial sarcoma (SS) constitutes 5–10% of all soft tissue sarcomas (STS) [Anthracyclines constitute the frontline treatment for advanced SS, with response rates of 16–27% demonstrated across all STS subtypes [Gemcitabine and docetaxel (GD) form a synergistic cytotoxic combination when docetaxel is sequentially administered after gemcitabine, as demonstrated by Leu et al. in in-vitro and in-vivo analyses [